A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 547-553

  Esteban, Jaime ^a   Gadea, I ^a   Torres, M V ^a   Cabria, F ^a   Rollan, E ^a   Santos O'Connor, F G ^a   Fernandez Roblas R ^a   Soriano, F ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Disk diffusion; Mycobacterium chelonae; Mycobacterium fortuitum; Rapidly growing mycobacteria; Susceptibility

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; TETRACYCLINE;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISK DIFFUSION; INTERMETHOD COMPARISON; MICRODILUTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM FORTUITUM; NONHUMAN; RELIABILITY; SPECIES DIFFERENCE; TECHNIQUE;

EID: 0036972397     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.547     Document Type: Article

References (23)

1. Martín-Casabona N, Rosselló-Urgell J, Ambientales GdEsM. [Environmental mycobacteria in Spain: Isolates from the 1976-1996 period]. Med Clín (Barc) 2000; 115: 663-670.
2. Esteban J, Fernandez-Roblas R, Soriano F. [Rapidly growing mycobacteria in human pathology]. Enf Infec Microbiol Clín 2000; 18(6): 279-286.
3. Griffith DE, Girard WM, Wallace RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am Rev Resp Dis 1993; 147: 1271-1278.
4. Wallace RJ, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5: 657-679.
5. Wallace RJ. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae. Clin Chest Med 1989; 10(3): 419-429.
6. Wallace RJ, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166: 405-412.
7. Wallace RJ, Silcox VA, Tsukamura M, Brown BA, Kilburn JO, Butler WR, et al. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J Clin Microbiol 1993; 31: 3231-3239.
8. Wallace RJ, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152(3): 500-514.
9. Wallace RJ, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am J Resp Crit Care Med 1997; 156: S1-S25.
10. Stone MS, Wallace RJJ, Swenson JM, Thornsberry C, Christensen LA. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother 1983; 24(4): 486-93.
11. Swenson JM, Wallace RJJ, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae [published erratum appears in Antimicrob Agents Chemother 1986 Apr;29(4):720]. Antimicrob Agents Chemother 1985; 28(6): 807-11.
12. Swenson JM, Thornsberry C, Silcox VA. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother 1982; 22(2): 186-92.
13. Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Wanger A, Boulet B, et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 1999; 37(6): 1676-82.
14. Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Boulet B, Plaunt M, et al. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 2000; 38(2): 656-61.
15. Hoffner SE, Klintz L, Olsson-Liljequist B, Bolmstrom A. Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum. J Clin Microbiol 1994; 32(8): 1846-9.
16. Wallace RJJ, Dalovisio JR, Pankey GA. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. Antimicrob Agents Chemother 1979; 16(5): 611-4.
17. Orefici G, Scopetti F. Susceptibility of Mycobacterium fortuitum to antibacterial agents as evaluated by disk diffusion and agar dilution methods. Bollettino Dell Istituto Sieroterapico Milanese 1983; 62(5): 402-5.
18. Ferra Salazar C, Montoro Cardoso E, Valdivia Alvarez J, Jimenez Misas C, Diaz Rodriguez R. [Mycobacterium fortuitum: the determination of its susceptibility by the disk diffusion technic]. Rev Cub Med Trop 1992; 44(1): 17-20.
19. Casal M, Rodriguez F. [Study of in vitro susceptibility of Mycobacterium fortuitum to aminoglycoside and beta-lactam antibiotics (author's transl)]. Ann Microbiol 1981; 132B (1): 51-6.
20. Casal MJ, Rodriguez FC. In vitro susceptibility of Mycobacterium fortuitum to non-antituberculous antibacterial agents. Ann Microbiol 1983; 134A (1): 73-8.
21. Fernandez-Roblas R, Esteban J, Cabria F, Lopez JC, Jimenez MS, Soriano F. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000; 44 (1): 181-2.
22. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44 (3): 393-5.
23. Khardori N, Nguyen H, Rosenbaum B, Rolston K, Bodey GP. In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents. Antimicrob Agents Chemother 1994; 38 (1): 134-7.